Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT02091999
Title A Study of Escalating Doses of ASG-22CE Given as Monotherapy in Subjects With Metastatic Urothelial Cancer and Other Malignant Solid Tumors That Express Nectin-4
Recruitment Active, not recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors Astellas Pharma Global Development, Inc.
Indications

lung non-small cell carcinoma

peritoneal carcinoma

urethra transitional cell carcinoma

fallopian tube cancer

ovary epithelial cancer

ureter transitional cell carcinoma

bladder urothelial carcinoma

renal pelvis transitional cell carcinoma

Therapies

Enfortumab vedotin-ejfv

Age Groups: adult | senior
Covered Countries USA | CAN


No variant requirements are available.